Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARQT Arcutis Biotherapeutics Inc.

Post-Market Trading 03-31 16:14:00 EDT

15.64

-0.09

-0.57%

盘后15.51

-0.13-0.83%

16:10 EDT

High16.11	Low14.76	Vol3.06M
Open15.10	D1 Closing15.73	Amplitude8.58%
Mkt Cap1.86B	Tradable Cap1.33B	Total Shares118.64M
T/O47.61M	T/O Rate3.59%	Tradable Shares85.24M
P/B11.78	ROE-113.76%	EPS-1.16
52wk High17.75	52wk Low6.99	P/E-13.51
Dividend0.00	Div.Yield0.00	ROA-23.25%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":15.64,"timestamp":1743451200000,"preClose":15.73,"halted":0,"volume":3060217,"hourTrading":{"tag":"盘后","latestPrice":15.51,"preClose":15.64,"latestTime":"16:10 EDT","volume":122438,"amount":1914930.197562,"timestamp":1743451834079},"delay":0,"floatShares":85240500,"shares":118638235,"eps":-1.157752,"marketStatus":"Post-Market Trading","change":-0.09,"latestTime":"03-31 16:14:00 EDT","open":15.1,"high":16.11,"low":14.76,"amount":47613083.923976004,"amplitude":0.085823,"askPrice":15.6,"askSize":300,"bidPrice":15.45,"bidSize":296,"shortable":3,"etf":0,"ttmEps":-1.157752,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":15.73,"preHourTrading":{"tag":"盘前","latestPrice":15.26,"preClose":15.73,"latestTime":"09:28 EDT","volume":15644,"amount":239317.860204,"timestamp":1743427685752},"postHourTrading":{"tag":"盘后","latestPrice":15.51,"preClose":15.64,"latestTime":"16:10 EDT","volume":122438,"amount":1914930.197562,"timestamp":1743451834079},"volumeRatio":1.523302,"impliedVol":0.8921,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"2522816504","title":"How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522816504","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522816504?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:55","pubTimestamp":1743170103,"startTime":"0","endTime":"0","summary":"Shares of Arcutis Biotherapeutics, Inc.  have gained 25.7% over the past four weeks to close the last trading session at $16.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $20.25 indicates a potential upside of 25.9%.However, an impressive consensus price target is not the only factor that indicates a potential upside in ARQT. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/much-upside-left-arcutis-biotherapeutics-135503493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2522950481","title":"Are Medical Stocks Lagging  Cardinal Health (CAH) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522950481","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522950481?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:40","pubTimestamp":1743169210,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Cardinal Health  one of those stocks right now?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cardinal Health is a member of our Medical group, which includes 1010 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cardinal Health is currently sporting a Zacks Rank of #2 .Based on the most recent data, CAH has r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-cardinal-health-134010319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","LU0211328371.USD","LU0792757196.USD","LU1571399168.USD","LU0162691827.USD","LU0072461881.USD","LU0310799852.SGD","LU0211327993.USD","LU1267930490.SGD","BK4585","LU0052756011.USD","BK4175","LU0310800965.SGD","LU0128525689.USD","LU1880398471.USD","BK4588","LU0154236417.USD","BK4139","LU1267930227.SGD","LU0889566641.SGD","CAH","LU0006061336.USD","SG9999001440.SGD","LU1880398554.USD","LU1267930813.SGD"],"gpt_icon":0},{"id":"2522303387","title":"Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303387?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 08:30","pubTimestamp":1742862623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), El...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","BK4007","BK4137","HCSG","ARQT","BK4139","ARVN"],"gpt_icon":0},{"id":"2520154145","title":"ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age","url":"https://stock-news.laohu8.com/highlight/detail?id=2520154145","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520154145?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control. Rapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis  Success at week 4, with significant improvements seen as early as week 1. Demonstrated efficacy and tolerability in treating facial involvement in AD, which affected 42% of trial participants. Shown to deliver sustained improvement in disease control for up to 56 weeks of treatment. TORONTO, March 17, 2025 /CNW/ - Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology,announced today that Health Canada has approved PrZORYVE , for the treatment of mild to moderate atopic dermatitis  in adults and children ages 6 years and older. The approval of this once-daily topical cream formulation of roflumilast marks a significant milestone, provi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zoryve-cream-0-15-approved-110000472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2520556199","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520556199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520556199?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 14:21","pubTimestamp":1742192460,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), Labco...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1059921491.USD","ARQT","VYGR","LH","BK4588","HCSG","BK4139","BK4585","BK4550","BK4137","BK4196","LU0006061336.USD"],"gpt_icon":0},{"id":"2518768577","title":"Arcutis Biotherapeutics Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768577?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 03:08","pubTimestamp":1741720080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARQT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 15:08 ET (19:08 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT"],"gpt_icon":0},{"id":"2518773876","title":"Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518773876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518773876?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 02:00","pubTimestamp":1741716012,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $19 from $16 and keeps a Buy rating on the shares. The firm views Arc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-price-target-raised-to-19-from-16-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-price-target-raised-to-19-from-16-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2518228064","title":"Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228064","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228064?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 22:03","pubTimestamp":1741529003,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shareholders would be excited to see that the share price has had a great...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-incs-nasdaqarqt-27-share-price-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","SQQQ","USJW.SI","QLD","TQQQ","TSYW.SI","ARQT","QID","IE00BGHQF748.EUR","BK4585","BK4139","NDAQ","LU2210150020.SGD","NQmain","BK4588","USAW.SI",".IXIC","LU2095319765.USD","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","NVIW.SI","IE00BKPKM429.USD","PSQ","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2517043480","title":"Arcutis Biotherapeutics announces new data from two posters at 2025 AAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2517043480","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517043480?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:11","pubTimestamp":1741353063,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting, AAD. The firs...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-announces-new-data-from-two-posters-at-2025-aad?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-announces-new-data-from-two-posters-at-2025-aad?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2517872614","title":"Arcutis Biotherapeutics Inc - Zoryve Cream 0.15% Shows Favorable Safety and Tolerability in Ad Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517872614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517872614?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:00","pubTimestamp":1741352401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nTUA3KZVTK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2517487259","title":"Arcutis to Highlight Data From Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83Rd American Academy of Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517487259?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:00","pubTimestamp":1741352401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nTUA3KZVTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2517487787","title":"Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487787","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517487787?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"Data demonstrated favorable safety and local tolerability of ZORYVE  cream 0.15% in adults and children with atopic dermatitis  with prior inadequate response, intolerance, and contraindications to topical treatments. New patient reported outcome data for investigational ZORYVE  foam 0.3% demonstrated favorable efficacy, safety, and local tolerability data in scalp and body psoriasis. In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and children, with more than half experiencing involvement of the scalp. “While topical therapies are the first line of therapy for millions of people with atopic dermatitis, there are many who are contraindicated or have an inadequate or intolerant response to topical therapies, which have previously been considered the standard of care. These data add to the large body of evidence that highlights the effectiveness, safety, and tolerability of ZORYVE cream 0.15% across divers","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-highlight-data-phase-3-130000285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","AFG","BK4139","BK4107","BK4117"],"gpt_icon":0},{"id":"2517616088","title":"Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average","url":"https://stock-news.laohu8.com/highlight/detail?id=2517616088","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517616088?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:30","pubTimestamp":1741271403,"startTime":"0","endTime":"0","summary":"From a technical perspective, Arcutis Biotherapeutics, Inc.  is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.Shares of ARQT have been moving higher over the past four weeks, up 12.1%. Plus, the company is currently a Zacks Rank #2  stock, suggesting that ARQT could be poised for a continued surge.Once investors consider ARQT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year, compared to 3 higher, and the consensus estimate has increased as well.Investors should think about putting ARQT on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-biotherapeutics-inc-arqt-just-143003988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2517929205","title":"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517929205?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:00","pubTimestamp":1741208400,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., March 05, 2025  -- Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-biotherapeutics-reports-inducement-grants-210000192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","BK4139","BK4588","BK4585","LU2210149790.SGD","BK4112","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","ARQT",".IXIC","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"1166577550","title":"Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1166577550","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166577550?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 04:48","pubTimestamp":1740775716,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.  saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ARQT"],"gpt_icon":0},{"id":"2514322136","title":"Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322136","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322136?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"One poster will share pooled INTEGUMENT data of ZORYVE  cream 0.15% in atopic dermatitis  in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroids. Second poster will highlight improvements in patient-related outcomes with ZORYVE  foam 0.3% in psoriasis of the scalp and body. WESTLAKE VILLAGE, Calif., Feb. 28, 2025  -- Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present two posters at the 2025 American Academy of Dermatology  annual meeting which will take place in Orlando, FL, from March 7 – 11, 2025.The Company will present data from two Phase 3 trials  demonstrating pooled safety and local tolerability of roflumilast cream 0.15% in adults and children down to age six with AD who had prior inadequate response, intolerance, and/or contraindications to topical treatments including topic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-present-two-posters-83rd-140000516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","BK4117","BK4107","AFG","BK4139"],"gpt_icon":0},{"id":"2514542325","title":"Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514542325","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514542325?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:37","pubTimestamp":1740742673,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics, Inc.  investors will be delighted, with the company turning in some strong numbers with its latest results. Results overall were credible, with revenues arriving 6.0% better than analyst forecasts at US$197m. Higher revenues also resulted in lower statutory losses, which were US$1.16 per share, some 6.0% smaller than the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.NasdaqGS:ARQT Earnings and Revenue Growth February 28th 2025. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-biotherapeutics-inc-nasdaq-arqt-113753688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NDAQ","ARQT"],"gpt_icon":0},{"id":"2514238068","title":"Arcutis Biotherapeutics Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514238068?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 00:50","pubTimestamp":1740675000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARQT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 11:50 ET (16:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT"],"gpt_icon":0},{"id":"2514805348","title":"Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805348","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514805348?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 19:35","pubTimestamp":1740656115,"startTime":"0","endTime":"0","summary":"NasdaqGS:ARQT Earnings and Revenue Growth February 27th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 6.0%. Earnings per share  also surpassed analyst estimates by 11%.Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 1.8% from a week ago.We don't want to rain on the parade too much, but we did also find 3 warning signs for Arcutis Biotherapeutics that you need to be mindful of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-biotherapeutics-full-2024-earnings-113515044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT"],"gpt_icon":0},{"id":"2514850078","title":"BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514850078","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514850078?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 00:56","pubTimestamp":1740588981,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL3N3PH1I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","NRG","BK4141","LU0109391861.USD","CZR","DLO","BK4099","FCX","SHW","SPNT","WBA","LU1023059493.AUD","SPOT","LU0823434740.USD","AXON","LU0823414551.USD","TJX","ADUS","BK4008","INTU","LHX","BBIO","AVDX","CAKE","GNL","LU0957791311.USD","OPCH","IMXI","NOC","TBLA","SCCO","LU0738911758.USD","UTHR","LU1720051017.SGD","RCUS","FLYW","SMCI","CART","SYTA","LCID","AAL","ARDX","LU0289961442.SGD","FSLR","MMM","SEZL","IE00B19Z9P08.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":-0.0752},{"period":"1month","weight":0.1899},{"period":"3month","weight":0.1},{"period":"6month","weight":0.6806},{"period":"1year","weight":0.5873},{"period":"ytd","weight":0.1292}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.117216},{"month":2,"riseRate":0.833333,"avgChangeRate":0.23515},{"month":3,"riseRate":0.5,"avgChangeRate":-0.026183},{"month":4,"riseRate":0.6,"avgChangeRate":0.060261},{"month":5,"riseRate":0.6,"avgChangeRate":-0.10059},{"month":6,"riseRate":0.8,"avgChangeRate":0.067805},{"month":7,"riseRate":0.6,"avgChangeRate":0.020773},{"month":8,"riseRate":0.4,"avgChangeRate":-0.035909},{"month":9,"riseRate":0.4,"avgChangeRate":-0.103428},{"month":10,"riseRate":0,"avgChangeRate":-0.25256},{"month":11,"riseRate":0.4,"avgChangeRate":0.133149},{"month":12,"riseRate":0.8,"avgChangeRate":0.194311}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction